Ilunocitinib

Veterinary medication From Wikipedia, the free encyclopedia

Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs.[1][3] It is a non-selective Janus kinase inhibitor.[3]

Pronunciation/aɪˌlʌnoʊˈsaɪtɪnɪb/
eye-LUN-oh-SYE-ti-nib
Trade namesZenrelia
Other namesLY-3411067
License data
Quick facts Clinical data, Pronunciation ...
Ilunocitinib
Clinical data
Pronunciation/aɪˌlʌnoʊˈsaɪtɪnɪb/
eye-LUN-oh-SYE-ti-nib
Trade namesZenrelia
Other namesLY-3411067
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-(1-(cyclopropanesulfonyl)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H17N7O2S
Molar mass383.43 g·mol−1
3D model (JSmol)
  • N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(S(=O)(=O)C2CC2)C1
  • InChI=InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)
  • Key:RVOUEXFKIYNODQ-UHFFFAOYSA-N
Close

Ilunocitinib was approved for medical use in the United States in September 2024,[4] and in it was approved in Canada in December 2024.[1]

Medical uses

Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age.[1][3][5]

Contraindications

It is not safe to administer vaccines to dogs that are concurrently receiving ilunocitinib.[5]

Society and culture

Ilunocitinib was approved for medical use in the United States in September 2024,[6] and in Canada in December 2024.[1]

In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Zenrelia, film-coated tablets, intended for dogs.[7] The applicant for this veterinary medicinal product is Elanco GmbH.[7]

Names

Ilunocitinib is the international nonproprietary name.[8]

Ilunocitinib is sold under the brand name Zenrelia.[1][3]

References

Related Articles

Wikiwand AI